Showing 15 posts of 150 posts found.

Boehringer’s lung cancer drug gets EMA nod

September 29, 2014
Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib

The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …

Boehringer image

Boehringer to slash 600 jobs in native Germany

September 24, 2014
Manufacturing and Production, Research and Development, Sales and Marketing AMNOG, Boehringer, Germany, Novartis, cuts, mergers, staff

Boehringer Ingelheim is to cut around 600 of its staff in Germany as part of a drive to reduce costs …

Lilly image

Lilly and Boehringer diabetes biosimilar sees EU approval

September 11, 2014
Sales and Marketing Boehringer, EU, European Commission, Lantus, Sanofi, diabetes, lilly

Lilly and Boehringer Ingelheim’s insulin glargine product has been shown the green light by the European Commission (EC). The copycat …

ERS event image

InterMune’s IPF drug shines at ERS Congress

September 10, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone

InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …

Ben Venue image

Ben Venue problems continue for Boehringer

September 2, 2014
Manufacturing and Production, Sales and Marketing Ben Venue, Boehringer, fad, german, manufacturing, recall

Boehringer Ingelheim’s tribulations at its US production site Ben Venue Laboratories are refusing to leave as more of its products …

InterMune image

InterMune stock jumps on suitor claims

August 14, 2014
Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune

Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …

Pradaxa image

BMJ investigation raises new concerns over Pradaxa

July 24, 2014
Medical Communications, Research and Development, Sales and Marketing BMJ, Boehringer, Channel 4, Pradaxa, blood, warfarin

An investigation by The BMJ has raised fresh concerns about Boehringer’s top-selling blood thinner Pradaxa (dabigatran) and the regulatory decisions …

hikma image

Hikma completes Bedford Laboratories purchase

July 16, 2014
Manufacturing and Production Ben Venue, Boehringer, Hikma, bedford laboratories

Hikma has completed its acquisition of assets of the US generic injectables business Bedford Laboratories from Ben Venue Laboratories, a …

Boehringer blood cancer drug scores in Phase II

July 9, 2014
Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib

Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …

Game image

Lilly launches online board game

June 24, 2014
Medical Communications, Sales and Marketing Boehringer, Gamification, Syrum, destination discovery, lillypad

Eli Lilly has created an online board game called ‘Destination Discovery’ that it says can help users enjoy the challenges …

boehringer image

Boehringer abandons hep C

June 23, 2014
Research and Development, Sales and Marketing AbbVie, Boehringer, HCV, faldaprevir, german, hep C

Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …

Pradaxa image

Pradaxa gets DVT indication

June 6, 2014
Sales and Marketing Boehringer, DVT, Pradaxa, blood, dabigatran etexilate, thinner

Pradaxa has been given approval in Europe to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) just a week …

EMA accepts Boehringer IPF drug

June 6, 2014
Sales and Marketing Boehringer, EMA, IPF, inpulsis, lung, nintedanib

Boehringer Ingelheim has moved a step closer to getting its investigational treatment nintedanib approved in Europe for a potentially fatal …

boehringer image

Boehringer lung cancer drug shows survival benefit

June 3, 2014
Sales and Marketing ASCO, Boehringer, NSCLC, afatinib, giotrif, lung cancer

A new analysis of two late-stage trials shows that Boehringer drug Giotrif extends overall survival in a large proportion of …

boehringer image

Boehringer settles US lawsuits

May 29, 2014
Medical Communications, Sales and Marketing Boehringer, Pradaxa, US, blood, lawsuits, warfarin

Boehringer Ingelheim has sought to bring to an end around 4,000 legal cases which have been brought against the company …

Latest content